Beijing Northland Biotechnology Co., Ltd. is an innovative biopharmaceutical enterprise specializing in the research, development, production, and sales of gene therapy drugs, recombinant protein drugs, and ophthalmic medications. Founded in June 2004, the company was among the first batch listed on the Beijing Stock Exchange in November 2021, with stock code 920047. The company is a key high-tech enterprise under the National Torch Program, a Beijing science and technology research and development institution, the Beijing Naked Plasmid Gene Therapy Drug Engineering Technology Research Center, a Beijing international science and technology cooperation base, a G20 innovation-leading enterprise in Beijing’s biopharmaceutical industry, and a “specialized, refined, distinctive, and innovative” small and medium-sized enterprise in Beijing.

The company boasts a highly qualified R&D and management team, with extensive experience in preclinical research, clinical trials, manufacturing and quality management, pharmaceutical plant construction, and drug distribution. It has established core technology platforms covering gene vector engineering, engineered microbial strain development, microbial expression, mammalian cell expression, biopharmaceutical manufacturing processes and scale-up technologies, as well as ophthalmic formulation development, thereby ensuring the sustained advancement of its pipeline. Guided by clinical needs and leveraging its proprietary technological platforms, the company is primarily focused on the research, development, and commercialization of innovative biologic medicines for cardiovascular diseases, metabolic disorders, rare diseases, and ocular conditions.

The company boasts a robust and highly mature drug R&D pipeline, currently advancing 11 bioengineered innovative drugs targeting 13 indications, with three already in clinical development. Among these, the recombinant human hepatocyte growth factor naked plasmid injection (code-named NL003) has completed Phase III clinical trials and submitted an NDA; the recombinant human interleukin‑11 for injection (code-named NL002) has entered Phase III; and the recombinant human thymosin β4 for injection (code-named NL005) is currently undergoing Phase II clinical studies. In addition, several ophthalmic products are being developed and brought to market in succession. The company holds 22 authorized patents and has undertaken eight national-level “Major New Drug Development” projects.

While maintaining a commitment to independent R&D, the company has established long-term, stable collaborations with pharmaceutical research institutions both domestically and internationally. Through joint development, technology transfer, and other collaborative models, it closely monitors global trends and advancements in biotechnology, ensuring its drug‑development capabilities remain cutting‑edge and compliant with international standards. In 2012, the company formed Beijing Huiren Land Pharmaceutical Co., Ltd. as a joint venture with the renowned Korean pharmaceutical firm Huons, introducing an advanced BFS system to specialize in the production of high‑quality ophthalmic products. The facility currently manufactures single‑dose and multi‑dose eye drops, with an annual production capacity of 110 million units. Additionally, the company offers CMO/CDMO services, providing customers with end‑to‑end solutions that integrate ophthalmic product design, R&D, and manufacturing.

Guided by the mission of “Creating Value, Serving Health,” the company is committed to becoming a leading enterprise in China’s gene therapy sector, making positive contributions to the advancement of China’s pharmaceutical industry and to human health.